Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing pharmaceutical products for the treatment of human disease. Its key products include ZYNQUISTA (sotagliflozin) for type 1 diabetes and INPEFA (sotagliflozin), a once-daily oral tablet that reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes, chronic kidney disease, and cardiovascular risk factors. The company also develops sotagliflozin for hypertrophic cardiomyopathy, LX9851 for obesity and cardiometabolic disorders, and pilavapadin (LX9211) for neuropathic pain. Lexicon has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company.

Lexicon Pharmaceuticals is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol LXRX. Its shares are traded in US dollars (USD). The company is headquartered in The Woodlands, Texas, and operates primarily in the United States.

Lexicon Pharmaceuticals operates in the Healthcare sector and specifically within the Biotechnology industry. As a biopharmaceutical company, it focuses on the discovery, development, and commercialization of innovative pharmaceutical products to treat serious human diseases, particularly in the areas of cardiology, diabetes, and pain management.

Lexicon Pharmaceuticals is headquartered in The Woodlands, Texas, United States. The company primarily serves the US market, as indicated by its US-based operations and regulatory approvals. Its products, such as INPEFA and ZYNQUISTA, are commercialized in the United States, and its development programs target diseases prevalent in the US population.

Lexicon Pharmaceuticals generates revenue primarily through the commercialization of its approved pharmaceutical products, including INPEFA (sotagliflozin) for heart failure and type 2 diabetes, and ZYNQUISTA (sotagliflozin) for type 1 diabetes. Additionally, the company benefits from strategic collaboration and license agreements with partners such as Viatris Inc. and Bristol-Myers Squibb Company, which may provide milestone payments, royalties, or other financial considerations. The company also invests in its pipeline of drug candidates, such as LX9851 for obesity and pilavapadin for neuropathic pain, which could generate future revenue upon approval and commercialization.